Equities research analysts expect Achaogen (NASDAQ:AKAO) to announce earnings of ($0.91) per share for the current quarter, according to Zacks. Five analysts have made estimates for Achaogen’s earnings. The lowest EPS estimate is ($1.02) and the highest is ($0.80). Achaogen posted earnings per share of ($0.51) during the same quarter last year, which would suggest a negative year-over-year growth rate of 78.4%. The company is scheduled to announce its next earnings report on Monday, May 14th.
On average, analysts expect that Achaogen will report full-year earnings of ($3.48) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($2.96). For the next financial year, analysts anticipate that the firm will report earnings of ($2.31) per share, with EPS estimates ranging from ($3.18) to ($1.59). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.21). The firm had revenue of $1.87 million for the quarter, compared to analysts’ expectations of $1.18 million. Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%.
AKAO has been the subject of a number of recent analyst reports. Guggenheim restated a “buy” rating and set a $14.00 price target on shares of Achaogen in a research report on Wednesday, January 10th. Needham & Company LLC restated a “buy” rating and set a $20.00 price target (down from $29.00) on shares of Achaogen in a research report on Wednesday, February 28th. Zacks Investment Research lowered shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Stifel Nicolaus reduced their price target on shares of Achaogen from $27.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Finally, HC Wainwright boosted their price target on shares of Achaogen from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. Achaogen presently has an average rating of “Buy” and an average target price of $23.56.
AKAO opened at $12.68 on Monday. The firm has a market cap of $551.91, a PE ratio of -4.00 and a beta of 1.04. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of 0.08. Achaogen has a one year low of $9.83 and a one year high of $27.49.
In other Achaogen news, major shareholder Robert W. Duggan purchased 527,396 shares of the stock in a transaction on Friday, March 2nd. The stock was acquired at an average cost of $10.31 per share, with a total value of $5,437,452.76. Following the completion of the purchase, the insider now directly owns 5,697,752 shares of the company’s stock, valued at approximately $58,743,823.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Robert W. Duggan purchased 10,000 shares of the stock in a transaction on Wednesday, February 14th. The stock was acquired at an average cost of $10.96 per share, with a total value of $109,600.00. Following the completion of the purchase, the insider now directly owns 5,668,310 shares of the company’s stock, valued at $62,124,677.60. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 810,717 shares of company stock valued at $8,739,717 and sold 10,089 shares valued at $110,576. 8.36% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of AKAO. Quantitative Investment Management LLC bought a new position in shares of Achaogen during the fourth quarter valued at about $1,433,000. Goldman Sachs Group Inc. raised its stake in shares of Achaogen by 2.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 331,039 shares of the biopharmaceutical company’s stock valued at $3,555,000 after acquiring an additional 9,267 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Achaogen by 12.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 137,716 shares of the biopharmaceutical company’s stock valued at $1,480,000 after acquiring an additional 15,032 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Achaogen by 375.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after acquiring an additional 14,725 shares during the last quarter. Finally, TimesSquare Capital Management LLC raised its stake in shares of Achaogen by 0.5% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,367,965 shares of the biopharmaceutical company’s stock valued at $14,692,000 after acquiring an additional 6,300 shares during the last quarter. 77.37% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Achaogen (AKAO) Will Post Earnings of -$0.91 Per Share” was originally posted by Macon Daily and is the property of of Macon Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://macondaily.com/2018/04/19/zacks-analysts-anticipate-achaogen-akao-will-post-earnings-of-0-91-per-share.html.
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Get a free copy of the Zacks research report on Achaogen (AKAO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.